MYR-001
Cancer & infectious disease
A small-molecule program targeting protein N-myristoylation, a dependency shared across certain cancers and infectious agents.
- Therapeutic area
- Oncology & Infectious Disease
- Target
- Undisclosed (myristoylation pathway)
- Modality
- Small Molecule
- Ownership
- Fully Owned
Why this program
A shared cellular dependency
N-myristoylation is a lipid modification that many proteins require to localize correctly and function. A range of tumors and infectious pathogens rely on this pathway more heavily than healthy human cells, which opens a potential therapeutic window.
One mechanism, two indications
Because the same enzymatic dependency appears in both oncology and infectious-disease settings, a single small-molecule series has the potential to address multiple indications from a common chemical starting point.
How we got here
AI-guided discovery
The program started as a question in Omic. The investigation screened large chemical spaces against the pathway and scored candidates with Omic’s discovery models for selectivity toward diseased over healthy cells. Every result is in the fabric, with its sources.
Where it stands
The program is in lead optimization, refining potency, selectivity, and drug-like properties. The specific molecular target remains undisclosed.